EA200101050A1 - Замещенные бензолактамные соединения - Google Patents
Замещенные бензолактамные соединенияInfo
- Publication number
- EA200101050A1 EA200101050A1 EA200101050A EA200101050A EA200101050A1 EA 200101050 A1 EA200101050 A1 EA 200101050A1 EA 200101050 A EA200101050 A EA 200101050A EA 200101050 A EA200101050 A EA 200101050A EA 200101050 A1 EA200101050 A1 EA 200101050A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- methyl
- relates
- present
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Настоящее изобретение относится к соединениям общей формулы (I)или к его фармацевтически приемлемым солям, где W, Т, Y, X, Q, R, R, и Rопределены в настоящем документе. Настоящее изобретение относится также к соединениям формулы (I), изображенной выше, в которой Y представляет собой -NH-; Т представляет собой (2S,3S)-2-фенилпиперидин-3-ил, где фенильная группа указанного (2S,3S)-2-фенилпиперидин-3-ила может быть, необязательно, замещена фтором; Q представляет собой кислород и соединен с атомом углерода двойной связью, Х представляет собой метокси или этокси, Rпредставляет собой водород, метил или галоген-С-Салкил, W представляет собой метилен, этилен или винилен; Rи Rнезависимо представляют собой водород или метил, или один из Rили Rможет представлять собой гидрокси, когда W представляет собой этилен, Rи Rоба представляют собой метил, когда W представляет собой метилен, и Rи Rоба представляют собой водород, когда W представляет собой винилен. Настоящее изобретение относится также к способам лечения различных заболеваний ЦНС и других заболеваний, при которых используют указанные соединения и их фармацевтические композиции.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13285899P | 1999-05-06 | 1999-05-06 | |
| PCT/IB2000/000461 WO2000068224A1 (en) | 1999-05-06 | 2000-04-13 | Substituted benzolactam compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200101050A1 true EA200101050A1 (ru) | 2002-04-25 |
Family
ID=22455915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200101050A EA200101050A1 (ru) | 1999-05-06 | 2000-04-13 | Замещенные бензолактамные соединения |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP1175417B1 (ru) |
| JP (1) | JP2002544128A (ru) |
| KR (1) | KR20020015319A (ru) |
| CN (1) | CN1349527A (ru) |
| AP (1) | AP2001002314A0 (ru) |
| AR (1) | AR036320A1 (ru) |
| AT (1) | ATE257478T1 (ru) |
| AU (1) | AU3572800A (ru) |
| BG (1) | BG106141A (ru) |
| BR (1) | BR0010673A (ru) |
| CA (1) | CA2373079A1 (ru) |
| CR (1) | CR6505A (ru) |
| CZ (1) | CZ20013977A3 (ru) |
| DE (1) | DE60007625T2 (ru) |
| DK (1) | DK1175417T3 (ru) |
| DZ (1) | DZ3040A1 (ru) |
| EA (1) | EA200101050A1 (ru) |
| EE (1) | EE200100586A (ru) |
| ES (1) | ES2211520T3 (ru) |
| GE (1) | GEP20043224B (ru) |
| GT (1) | GT200000063A (ru) |
| HK (1) | HK1046144A1 (ru) |
| HR (1) | HRP20010821A2 (ru) |
| HU (1) | HUP0201135A3 (ru) |
| IL (1) | IL145945A0 (ru) |
| IS (1) | IS6122A (ru) |
| MA (1) | MA26731A1 (ru) |
| MY (1) | MY133207A (ru) |
| NO (1) | NO20015395L (ru) |
| NZ (1) | NZ514697A (ru) |
| OA (1) | OA11864A (ru) |
| PA (1) | PA8494901A1 (ru) |
| PE (1) | PE20010119A1 (ru) |
| PL (1) | PL351919A1 (ru) |
| PT (1) | PT1175417E (ru) |
| TN (1) | TNSN00095A1 (ru) |
| TR (1) | TR200103222T2 (ru) |
| UY (1) | UY26135A1 (ru) |
| WO (1) | WO2000068224A1 (ru) |
| ZA (1) | ZA200109116B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2652135C2 (ru) * | 2013-11-08 | 2018-04-25 | Сумитомо Кемикал Компани, Лимитед | Сукцинимидное соединение |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108982D0 (en) | 2001-04-10 | 2001-05-30 | Merck Sharp & Dohme | Therapeutic agents |
| EP1460061A4 (en) * | 2001-12-27 | 2006-05-31 | Toray Finechemicals Co Ltd | PROCESS FOR PRODUCING 1-ALCOXYCARBONYL SATURATED NITROGENIC HETEROCYCLIC DERIVATIVE |
| EP1613348B1 (en) | 2003-03-12 | 2010-06-23 | The Arizona Board of Regents on Behalf of the University of Arizona | Methods for modulating angiogenesis with apelin compositions |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2009109001A1 (en) * | 2008-03-04 | 2009-09-11 | Adelaide Research & Innovation Pty Ltd | Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE194340T1 (de) * | 1992-12-10 | 2000-07-15 | Pfizer | Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten |
| EP0840732B1 (en) * | 1995-07-07 | 2001-03-07 | Pfizer Inc. | Substituted benzolactam compounds as substance p antagonists |
| TW340842B (en) * | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
| DK0780375T3 (da) * | 1995-12-21 | 2002-10-07 | Pfizer | 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
-
2000
- 2000-04-13 WO PCT/IB2000/000461 patent/WO2000068224A1/en not_active Application Discontinuation
- 2000-04-13 KR KR1020017014110A patent/KR20020015319A/ko not_active Ceased
- 2000-04-13 AT AT00914335T patent/ATE257478T1/de not_active IP Right Cessation
- 2000-04-13 GE GEAP20006190A patent/GEP20043224B/en unknown
- 2000-04-13 CA CA002373079A patent/CA2373079A1/en not_active Abandoned
- 2000-04-13 HU HU0201135A patent/HUP0201135A3/hu unknown
- 2000-04-13 AU AU35728/00A patent/AU3572800A/en not_active Abandoned
- 2000-04-13 OA OA1200100264A patent/OA11864A/en unknown
- 2000-04-13 HR HR20010821A patent/HRP20010821A2/hr not_active Application Discontinuation
- 2000-04-13 CZ CZ20013977A patent/CZ20013977A3/cs unknown
- 2000-04-13 EA EA200101050A patent/EA200101050A1/ru unknown
- 2000-04-13 EP EP00914335A patent/EP1175417B1/en not_active Expired - Lifetime
- 2000-04-13 PL PL00351919A patent/PL351919A1/xx not_active Application Discontinuation
- 2000-04-13 JP JP2000616198A patent/JP2002544128A/ja active Pending
- 2000-04-13 AP APAP/P/2001/002314A patent/AP2001002314A0/en unknown
- 2000-04-13 PT PT00914335T patent/PT1175417E/pt unknown
- 2000-04-13 ES ES00914335T patent/ES2211520T3/es not_active Expired - Lifetime
- 2000-04-13 HK HK02107807.6A patent/HK1046144A1/zh unknown
- 2000-04-13 DK DK00914335T patent/DK1175417T3/da active
- 2000-04-13 DE DE2000607625 patent/DE60007625T2/de not_active Expired - Fee Related
- 2000-04-13 TR TR2001/03222T patent/TR200103222T2/xx unknown
- 2000-04-13 EE EEP200100586A patent/EE200100586A/xx unknown
- 2000-04-13 NZ NZ514697A patent/NZ514697A/en unknown
- 2000-04-13 BR BR0010673-9A patent/BR0010673A/pt not_active IP Right Cessation
- 2000-04-13 CN CN00807267A patent/CN1349527A/zh active Pending
- 2000-04-13 IL IL14594500A patent/IL145945A0/xx unknown
- 2000-05-03 DZ DZ000082A patent/DZ3040A1/xx active
- 2000-05-03 PA PA20008494901A patent/PA8494901A1/es unknown
- 2000-05-03 TN TNTNSN00095A patent/TNSN00095A1/fr unknown
- 2000-05-03 UY UY26135A patent/UY26135A1/es not_active Application Discontinuation
- 2000-05-03 MA MA25966A patent/MA26731A1/fr unknown
- 2000-05-04 MY MYPI20001922A patent/MY133207A/en unknown
- 2000-05-04 AR ARP000102150A patent/AR036320A1/es unknown
- 2000-05-05 GT GT200000063A patent/GT200000063A/es unknown
- 2000-05-05 PE PE2000000418A patent/PE20010119A1/es not_active Application Discontinuation
-
2001
- 2001-10-23 IS IS6122A patent/IS6122A/is unknown
- 2001-11-05 NO NO20015395A patent/NO20015395L/no not_active Application Discontinuation
- 2001-11-05 ZA ZA200109116A patent/ZA200109116B/en unknown
- 2001-11-19 CR CR6505A patent/CR6505A/es not_active Application Discontinuation
- 2001-11-23 BG BG106141A patent/BG106141A/bg unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2652135C2 (ru) * | 2013-11-08 | 2018-04-25 | Сумитомо Кемикал Компани, Лимитед | Сукцинимидное соединение |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1485359T3 (da) | Natriumkanalblokkere | |
| DK1325910T3 (da) | Aliphatiske nitrogenholdige femleddede ringforbindelser | |
| MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
| EA200100755A1 (ru) | 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты | |
| EA200101194A1 (ru) | Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств | |
| EA200600358A1 (ru) | Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2 | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| ATE306261T1 (de) | Antithrombosemittel | |
| EA200100970A1 (ru) | Аминопроизводные как ингибиторы протеазы | |
| IS6257A (is) | Frumuviðloðunartálmar | |
| EA200100310A1 (ru) | Кислородсодержащие гетероциклические соединения | |
| EA200300982A1 (ru) | Гетероциклические производные для лечения рака и других пролиферативных заболеваний | |
| EA200000614A1 (ru) | 2,3-замещенные соединения индола в качестве ингибиторов сох-2 | |
| ATE374773T1 (de) | Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten | |
| HRP20000585B1 (en) | Substituted bisindolymaleimides for the inhibition of cell proliferation | |
| ATE308540T1 (de) | Antithrombosemittel | |
| EA200101050A1 (ru) | Замещенные бензолактамные соединения | |
| EA200200041A1 (ru) | Новые четвертичные соединения аммония, способ их получения и фармацевтическое применение | |
| EA200101209A1 (ru) | Новые производные бензола, способ их получения и фармацевтические композиции, содержащие их | |
| EA200500032A1 (ru) | Производные ацилоксипирролидина и их применение в качестве лигандов v1b или v1b и v1a рецепторов | |
| ATE151750T1 (de) | 3-(indol-3-yl) propensäurderivate, die als nmda- antagonisten nützlich sind | |
| DK1347960T3 (da) | Fremgangsmåde til fremstilling af (+/-) trans-4-p-fluorphenyl-3-hydromethyl-1-methylpiperidin | |
| EA200200292A1 (ru) | Производные гигромицина |